Lilly Weight Loss Drug Trials
3 outlets
3 reporters
- Alice ParkTime
- Berkeley Lovelace Jr.NBC News
- Zoe HardyDaily Mail
By day
Articles per day
Cite
Lilly Weight Loss Drug Trials. (2026, October 13). The Aporia. https://theaporia.onrender.com/event/44760
“Lilly Weight Loss Drug Trials.” The Aporia, 13 Oct. 2026, https://theaporia.onrender.com/event/44760.
“Lilly Weight Loss Drug Trials.” The Aporia, October 13, 2026. https://theaporia.onrender.com/event/44760.
Dated the day this page was built. The link always leads to this event, even after the stories are regrouped.
One study, published in the Lancet and presented at the European Association for the Study of Diabetes, tested the drug retatrutide in people who were overweight or obese and had Type 2 diabetes: a population in which weight-loss medications have historically been less effective.
What happened
The outlets' own sentences, most widely reported first. Hover or tap one to see who reported it.
What each outlet says
One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.
Eli Lilly’s experimental weight-loss drug, retatrutide, showed significant effectiveness in two studies published in The Lancet and the New England Journal of Medicine. Participants with Type 2 diabetes who took the highest dose lost an average of 18.8% of their body weight over a year and a half, compared to 5.1% for those on placebo. In a separate study focusing on overweight or obese individuals without diabetes…
Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results →Eli Lilly's GLP-1 drug retatrutide helped people with Type 2 diabetes lose up to 60 pounds, or about 23% of their body weight, according to a late-stage trial published in The Lancet. This result is the highest recorded weight loss for a diabetes medication and compares favorably to semaglutide and tirzepatide, which resulted in up to 10% and 15% weight loss respectively. Dr. Susan Spratt of Duke Health highlighted…
People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug →A new drug called Retatrutide, nicknamed the 'Godzilla' fat jab or 'Reta', is showing promising results in clinical trials for weight loss among obese patients with type 2 diabetes. In a phase 3 trial involving 1,152 participants from eight countries, those on the highest dose of Retatrutide lost up to a quarter of their body weight over 18 months, compared to around 20% for Mounjaro over a similar period. The drug…
'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain →Analysis
Framing
How the first headlines put it
The headlines (3)
Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results
People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain
How it changed
- 29 Sep
One study, published in the Lancet and presented at the European Association for the Study of Diabetes, tested the drug retatrutide in people who were overweight or obese and had Type 2 diabetes: a population in which weight-loss medications have historically been less effective.
Coverage 3 articles
Suggested from 3 outlets: the fullest account of the event, no political position was found in its wording and its publisher is declared as reporting rather than commentary.
30 Sep 'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in BritainA new drug called Retatrutide, nicknamed the 'Godzilla' fat jab or 'Reta', is showing promising results in clinical trials for weight loss among obese patients with type 2 diabetes. In a phase 3 trial involving 1,152 participants from eight countries, those on the highest dose of Retatrutide lost up to a quarter of their body weight over 18 months, compared to around 20% for Mounjaro over a similar period. The drug…Daily Mail
29 Sep People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drugEli Lilly's GLP-1 drug retatrutide helped people with Type 2 diabetes lose up to 60 pounds, or about 23% of their body weight, according to a late-stage trial published in The Lancet. This result is the highest recorded weight loss for a diabetes medication and compares favorably to semaglutide and tirzepatide, which resulted in up to 10% and 15% weight loss respectively. Dr. Susan Spratt of Duke Health highlighted…NBC News
29 Sep Eli Lilly’s Experimental Weight-Loss Drug Shows Promising ResultsEli Lilly’s experimental weight-loss drug, retatrutide, showed significant effectiveness in two studies published in The Lancet and the New England Journal of Medicine. Participants with Type 2 diabetes who took the highest dose lost an average of 18.8% of their body weight over a year and a half, compared to 5.1% for those on placebo. In a separate study focusing on overweight or obese individuals without diabetes…Time
Keep exploring
Similar coverage · 23 SepWeight Loss Jabs Trend
Similar coverage · 22 SepGLP-1 Drug Lawsuits Vision Loss
Similar coverage · 7 OctWHO Guidance On Child ObesityTreatment
Similar coverage · 21 SepPritzker Weight Loss And Politics
Recent · 6–12 NovNvidia CEO Scandal and Spy Allegations
Recent · 10–12 NovThree Iranians Indicted For Terror Plots
Recent · 9–12 NovRacist Incidents at Ole Miss
Recent · 10–11 NovTrump Defamation Case Against BBC Proceeds
Recent · 11–12 NovHegseth Group Reprimanded At Tomb
Recent · 4–12 NovMississippi Senate Race Uncertainty
Built 2026-10-13 from 3 articles. Every sentence on this page is quoted from the linked article; nothing was written by a model except the Summary and the items marked AI, which cite their sources, and the questions and labels under "Disputed". Photos are from the outlets that covered the story, never from articles our check marks sensitive.